Zhongtong Finance APP news, ch biotech ser (08037) announced that its indirect non-wholly-owned subsidiary shanghai longyao biotechnology co., ltd. (shanghai longyao) will exhibit at the 66th annual meeting of the American Society of Hematology in poster form, presenting updated clinical trial results of Phase I clinical study using LY007 cell injection (a new CD20-targeting autologous chimeric antigen receptor T-cell therapy product independently developed by shanghai longyao) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL).

Large B-cell lymphoma (LBCL) is a common subtype of B-NHL, with most patients being curable through standard immunotherapy regimens. However, about 40% of patients still face the challenge of relapsed or refractory disease after first-line treatment. The Phase I study, which started in 2021, aims to evaluate the safety and tolerability of using LY007 cell injection in treating patients with relapsed or refractory B-NHL. As of now, the Phase I study has shown that LY007 cell injection is well tolerated at dose levels of up to 5.0 x 106 cells/kg and demonstrates a promising dose-response relationship in treating relapsed or refractory B-NHL. It is expected that LY007 cell injection will provide a new curative treatment option for patients with large B-cell lymphoma.